Arrowhead Pharmaceuticals, Inc.

Equities

ARWR

US04280A1007

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:00:00 17/05/2024 BST			5-day change	1st Jan Change
24.77 ^USD	-0.92%		+0.20%	-19.05%

05-16	Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:40 AM
05-10	UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating	MT

Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023

November 29, 2023 at 09:01 pm

Arrowhead Pharmaceuticals, Inc. reported earnings results for the full year ended September 30, 2023. For the full year, the company reported sales was USD 240.74 million compared to USD 243.23 million a year ago. Net loss was USD 205.28 million compared to USD 176.06 million a year ago.

Diluted loss per share from continuing operations was USD 1.92 compared to USD 1.67 a year ago.

Latest news about Arrowhead Pharmaceuticals, Inc.

Transcript : Arrowhead Pharmaceuticals, Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 08:40 AM	05-16
UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating	05-10	MT
Arrowhead Pharmaceuticals Swings to Loss in Fiscal Q2	05-09	MT
Transcript : Arrowhead Pharmaceuticals, Inc., Q2 2024 Earnings Call, May 09, 2024	05-09
Arrowhead Nets $50 Milestone Payment from Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug	05-03	MT
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-CFB for Treatment of Complement Mediated Kidney Disease	04-24	CI
Arrowhead Pharmaceuticals, Inc. Announces New Phase 2 Data of Plozasiran Published in JAMA Cardiology and Presented at American College of Cardiology 73rd Annual Scientific Session & Expo	04-07	CI
Arrowhead Pharmaceuticals, Inc. Initiates Expanded Access Program for Plozasiran	03-25	CI
Arrowhead Doses First Subjects in Phase 1/2a Study of Myotonic Dystrophy Treatment; Shares Rise	03-08	MT
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DM1 for Treatment of Type 1 Myotonic Dystrophy	03-08	CI
Certain Restricted Stock Units of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.	03-02	CI
Certain Common Stock of Arrowhead Pharmaceuticals, Inc. are subject to a Lock-Up Agreement Ending on 3-MAR-2024.	03-02	CI
Arrowhead Pharmaceuticals, Inc. Appoints Hongbo Lu as Independent Director, Effective April 1, 2024	02-22	CI
B. Riley Adjusts Arrowhead Pharmaceuticals' PT to $55 From $50, Keeps Buy Rating	02-08	MT
Sector Update: Health Care Stocks Firmer Late Afternoon	02-07	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	02-07	MT
UBS Adjusts Price Target on Arrowhead Pharmaceuticals to $75 From $78, Maintains Buy Rating	02-07	MT
Sector Update: Health Care Stocks Mixed Premarket Wednesday	02-07	MT
Arrowhead Pharmaceuticals Fiscal Q1 Loss Widens, Revenue Declines	02-07	MT
Transcript : Arrowhead Pharmaceuticals, Inc., Q1 2024 Earnings Call, Feb 06, 2024	02-06
Arrowhead Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	02-06	CI
Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,860,019, According to a Recent SEC Filing	02-02	MT
Arrowhead Pharmaceuticals, Inc. Announces Leaving of Javier San Martin, M.D., as the Chief Medical Officer, Effective from February 1, 2024	01-22	CI
Arrowhead Pharmaceuticals Insider Sold Shares Worth $292,804, According to a Recent SEC Filing	01-08	MT
Arrowhead Pharmaceuticals Insider Sold Shares Worth $567,910, According to a Recent SEC Filing	01-08	MT

Chart Arrowhead Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 14 clinical-stage investigational medicines (nine wholly owned and five partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MUC5AC, ARO-MMP7, GSK-4532990, Fazirsiran, JNJ-3989, HZN-457, ARO-C3, ARO-PNPLA3, ARO-DUX4 and ARO-SOD1.

Sector

Biotechnology & Medical Research

Calendar

19/05/2024 - American Thoracic Society Conference - ARO-RAGE

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Arrowhead Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

25 USD

Average target price

53.77 USD

Spread / Average Target

+115.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
ARROWHEAD PHARMACEUTICALS, INC.	-19.05%	3.11B
VERTEX PHARMACEUTICALS INCORPORATED	+9.42%	114B
REGENERON PHARMACEUTICALS, INC.	+11.84%	104B
BIONTECH SE	-14.15%	22.41B
ARGENX SE	-1.05%	22.28B
GENMAB A/S	-5.29%	19.07B
WUXI APPTEC CO., LTD.	-38.29%	18B
BEIGENE, LTD.	-4.16%	17.89B
NEUROCRINE BIOSCIENCES, INC.	+7.99%	14.28B
SAREPTA THERAPEUTICS, INC.	+36.24%	12.55B

Bio Therapeutic Drugs